Oragenics is biopharmaceutical company. Its aim is to develop products through human proof-of-concept prior to partnering with major pharmaceutical, biotechnology or health care product firms for advanced clinical development and commercialization. It has developed a number of products, including replacement therapy, which is a single, painless topical treatment that offers protection from tooth decay; Mutacin 1140 is an antibiotic with activity against Gram-positive bacteria; oral probiotic technology, which employs naturally occurring beneficial bacteria to promote dental and periodontal health; in vivo-induced antigen technology, which provides a method for identification of new targets for use in the diagnosis and prevention of infectious diseases; and change mediated antigen technology, which identifies targets for diagnosis and treatment of cancers and other diseases in humans and other living organisms, including plants. Oragenics is headquartered in Alachua, Fla. It trades on the American Stock Exchange under the symbol ONI.